Lindbrook Capital LLC Buys 346 Shares of Novo Nordisk A/S (NYSE:NVO)

Lindbrook Capital LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,735 shares of the company’s stock after acquiring an additional 346 shares during the period. Lindbrook Capital LLC’s holdings in Novo Nordisk A/S were worth $1,278,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bridges Investment Management Inc. boosted its holdings in Novo Nordisk A/S by 2.0% in the 3rd quarter. Bridges Investment Management Inc. now owns 7,700 shares of the company’s stock valued at $917,000 after purchasing an additional 150 shares during the period. Wealth Quarterback LLC acquired a new position in Novo Nordisk A/S in the third quarter valued at about $856,000. Assetmark Inc. grew its stake in Novo Nordisk A/S by 5.1% during the third quarter. Assetmark Inc. now owns 441,882 shares of the company’s stock worth $52,615,000 after buying an additional 21,553 shares in the last quarter. Verdence Capital Advisors LLC raised its position in shares of Novo Nordisk A/S by 18.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 42,977 shares of the company’s stock valued at $5,117,000 after buying an additional 6,821 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NVO. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $107.23 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The stock has a market cap of $481.20 billion, a PE ratio of 34.70, a PEG ratio of 1.44 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The business has a 50-day simple moving average of $121.42 and a two-hundred day simple moving average of $130.30.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 89.69%. The firm had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Analysts anticipate that Novo Nordisk A/S will post 2.87 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.